Immunoassay instrument is gaining rapid adoption in the gene-based analysis especially for oncology

 


Immunoassays, or DNA assays, are a method of DNA analysis. DNA is the basis of all biological material, including the DNA of living organisms, cells, and tissues. This method can be used to analyze, identify, and profile various biological samples. The analysis of DNA has developed greatly over the years, due to the ability to conduct DNA tests on living people.

The use of immunoassays for gene-based analysis has grown tremendously. Primarily, immunoassay analysis is used to evaluate gene-based treatments in oncology, cardiovascular, orthopedics, infectious diseases, and clinical diagnostics. Currently, the primary uses of immunoassays are for the evaluation of gene-based therapies in oncology and cardiovascular clinical trials.

The analysis and measurement of immune parameters by immunoassay instruments are known as response curve analysis (RCA). The first analysis of RCA was done by Ward and coworkers in 1980, using monoclonal antibodies to stimulate the lymphocytes Subsequent immunoassay measurement models and systems have been developed to extend the scope of research and to make immunoassay measurement more cost-effective. As part of the global research effort on the future of Immunoassay Instruments.

There are other uses for immunoassays other than the medical diagnosis and staging of infectious diseases. In the pharmaceutical and bio-medical industries, these instruments are often used for the direct quantification and analysis of the efficiency and toxicity of therapeutic drugs in clinical trials and/or manufacturing processes. In addition, immunoassay systems are also used in the Food and Drug Administration (FDA) to determine the concentration of contaminants in manufactured pharmaceuticals. And sometimes, they are used to test the effects of new drugs on humans when they are administered in patients with preexisting disease.

Comments